No direct molecular target and fusion proteins

The designation "No direct molecular target and fusion proteins" is a non-specific classification used in pharmacological databases to identify therapeutic agents that do not interact with a discrete protein, receptor, or enzyme. This category encompasses drugs that function through physical or chemical means, such as osmotic agents like mannitol or pH buffers like antacids, which lack a traditional lock-and-key molecular interaction [Merck Manual Professional Version, 2023]. It also serves as a grouping for fusion proteins—chimeric molecules created through genetic engineering—which may act as decoys or signaling modulators rather than being the target themselves in a conventional sense [National Human Genome Research Institute, 2024]. In clinical contexts, this designation highlights the diversity of drug mechanisms that fall outside the standard receptor-ligand paradigm [StatPearls, 2023]. Because it represents a heterogeneous group of mechanisms rather than a single biological entity, it cannot be mapped to a specific gene or UniProt entry [EMBL-EBI ChEMBL Database, 2024]. This classification is essential for maintaining database integrity when a drug's efficacy is well-established but its mechanism is non-molecular or involves complex protein engineering [Nature Reviews Drug Discovery, 2022].

Other names

Non-specific targetNon-molecular mechanismFusion protein categoryNo direct molecular target

Therapeutic effects are achieved through physical properties, chemical neutralization, or the use of engineered chimeric proteins rather than binding to a specific endogenous molecular target [Merck Manual Professional Version, 2023; Nature Reviews Drug Discovery, 2022].